Catalent has expanded the services and capabilities at its facility in Shiga, Japan, to include the storage, kitting, and distribution of advanced therapies at ultra-low temperatures for clinical trials.

State-of-the-art cryogenic freezers alongside material transfer equipment have been installed that are designed to retain the integrity of investigational advanced therapy products by minimizing their time-out-of-environment. The expansion forms part of Catalent's ongoing global strategy to increase its ability to handle, store and manage advanced therapies for clinical supply, and follows investments at its facilities in Philadelphia, Singapore, and Shanghai, China, in specialised, ultra-low temperature storage capabilities.

The 6,000-square-meter Shiga site opened in October 2021 to support customers both locally and globally, providing flexible clinical supply solutions, including primary packaging, Catalent's FastChain demand-led supply, white glove handling and logistics.

"The market in Japan for advanced therapies and new modalities continues to grow, along with the demand for companies such as Catalent that have the advanced infrastructure to handle the supply and distribution of these highly sensitive products, as well as the specialized expertise and comprehensive knowledge to manage these supply chains," commented Tadahiro Matsumura, Catalent's President of Japan. 

Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year.